Several studies have demonstrated that immunotherapy is the most effective treatment, with one study describing that combining ipilimumab with a programmed cell death protein 1 inhibitor (nivolumab) yields the highest response rate.14 Per current surveillance protocols, PET/CT of the chest/abdomen/pelvis and magnetic resonance imaging/CT brain is recommended every 2–3 months for locoregional or metastatic disease. Here, PDCD1 is linked to metastatic neoplasm.